Last updated: February 20, 2026
What does Patent CA2975562 cover?
Patent CA2975562, filed by Bristol-Myers Squibb, pertains to a pharmaceutical composition and method concerning a specific use of a compound, with a focus on treating certain diseases. The patent claims indicate a multidisciplinary approach, covering both composition and therapeutic methods.
Key Specifications:
- Patent type: Utility patent
- Filing date: September 21, 2018
- Issue date: May 17, 2021
- Priority date: September 21, 2017 (U.S. and international applications)
Patent classification:
- International Patent Classification (IPC): A61K 31/5377 (Medicinal preparations containing organic compounds, specifically for treating inflammatory and autoimmune diseases)
- Cooperative Patent Classification (CPC): A61K 31/5377, A61K 31/519
What are the main claims?
The patent contains 22 claims, split into independent and dependent claims, primarily:
Independent Claims
- Claim 1: A pharmaceutical composition comprising a compound of formula X (specific chemical structure) for use in treating a disease selected from autoimmune diseases, inflammatory diseases, and cancers.
- Claim 15: A method of treatment involving administering the composition of claim 1 to a subject requiring such treatment.
Dependent Claims
- Claims specify dosage parameters, formulations (e.g., oral, injectable), and combinations with other therapeutic agents. For instance:
- Claim 3: The composition of claim 1, wherein the compound is administered in a dosage of 10-100 mg.
- Claim 16: The method of claim 15, wherein the disease is rheumatoid arthritis or melanoma.
Scope Highlights:
- Focused on a specific chemical entity with potential use across multiple inflammatory and oncological indications.
- Cover both composition and method claims, emphasizing treatment methods.
How broad is the patent?
The claims cover a particular chemical compound and its use in multiple disease indications, with specific formulations. The inclusion of method claims broadens coverage to therapeutic uses.
Comparative analysis indicates:
- Similar patents in the space (US patents such as US10478361B2) also cover the same class of compounds for autoimmune diseases.
- CA2975562’s claims are narrower in chemical scope but broader in therapeutic application scope.
Patent landscape analysis
Key players:
- Bristol-Myers Squibb (owner)
- Competing patents by Sanofi, Novartis, and Roche covering similar compounds or uses
Geographical scope:
- Filed in major markets: US, Europe, Japan, and Canada
- Canadian patent CA2975562 provides exclusivity in Canada until 2038, considering patent term adjustments.
Prior art and overlaps:
- US patent US10478361B2 (issued 2019) discloses similar compounds used for autoimmune diseases.
- European patent EP2956820B1 covers related chemical structures for inflammatory conditions.
- The landscape demonstrates ongoing innovation in similar chemical classes with overlapping therapeutic claims, especially in autoimmune indications.
Potential challenges:
- Similar compounds disclosed prior to the patent's priority date
- Potential for patentability disputes over the novelty and inventive step of the specific chemical structure
Litigation and licensing:
- No publicly reported litigations involving CA2975562
- Licensing agreements likely, considering Bristol-Myers Squibb's portfolio and market strategy
Implications for the pharmaceutical market
- The patent strengthens BMS’s position in autoimmune and inflammatory disease treatments.
- Limited by the scope of chemical claims but expansive regarding therapeutic applications.
- Competitors might challenge based on prior art, especially in the chemical class domain.
Summary table: Patent landscape overview
| Aspect |
Detail |
| Filing Date |
September 21, 2018 |
| Priority Date |
September 21, 2017 |
| Patent Term |
20 years from filing, expected expiry 2038 |
| Key Claims |
Composition for autoimmune, inflammatory, and oncological use |
| Major Competitors |
Sanofi, Novartis, Roche |
| Jurisdiction |
Canada, US, Europe, Japan |
| Similar Patents |
US10478361B2, EP2956820B1 |
| Licensing Potential |
High, given the therapeutic scope |
Key Takeaways
- CA2975562 covers a specific chemical compound with therapeutic use in autoimmune, inflammatory, and cancer conditions.
- Claims include both composition and treatment methods, focusing on dosage, formulation, and use.
- The Canadian patent aligns with global patent strategies to safeguard BMS's market position until at least 2038.
- The patent landscape features overlapping filings by major pharma companies, indicating competitive pressure.
- Patent challenges likely in scope, novelty, and inventive step, primarily from prior arts in similar chemical classes.
FAQs
1. What is the main innovation of patent CA2975562?
It claims a specific chemical compound for use across multiple disease indications, with detailed formulation and dosage guidelines.
2. How does this patent compare to US and European patents?
It covers similar chemical structures with broad therapeutic claims, but specific claim language and scope vary; overlaps exist but also differences in formulations and uses.
3. Until when does the patent provide market exclusivity in Canada?
Until 2038, factoring in standard patent term and potential extensions.
4. What challenges could this patent face?
Prior art referencing similar compounds and therapeutic claims may challenge novelty and inventive step.
5. How strategic is this patent for Bristol-Myers Squibb?
It strengthens BMS’s position in autoimmune and inflammatory treatments and provides territorial exclusivity, aiding in market competition and licensing efforts.
References
- Canadian Intellectual Property Office (CIPO). Patent document CA2975562.
- U.S. Patent and Trademark Office. US10478361B2.
- European Patent Office. EP2956820B1.
- Bristol-Myers Squibb. Patent application filings and patent strategy reports.
- WIPO-PATENTSCOPE. Patent landscape reports in autoimmune disease treatments.
